(Q35982338)

11 August 2017

Paradoxical effects of 5-FU/folinic acid on lymphokine-activated killer (LAK) cell induction in patients with colorectal cancer (English)

1 reference

11 August 2017

1 reference

Onodera H

1

1 reference

11 August 2017

Somers SS

series ordinal

2

1 reference

11 August 2017

Guillou PJ

series ordinal

3

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 December 1990

1 reference

British Journal of Cancer

11 August 2017

1 reference

11 August 2017

62

1 reference

11 August 2017

6

1 reference

11 August 2017

1042-1046

1 reference

Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells

11 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971584

Lymphokine activated killer (LAK) cells in patients with gastrointestinal cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971584

Reduction of toxicity of interleukin-2 and lymphokine-activated killer cells in humans by the administration of corticosteroids

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971584

Decreased interleukin-2 production in patients with gastrointestinal cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971584

Efficacy of chemoimmunotherapy with cyclophosphamide, interleukin-2 and lymphokine activated killer cells in an intraperitoneal murine tumour model

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971584

Induction of lymphokine-activated killer-like cells by cancer chemotherapy

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971584

A phase-II trial of recombinant interleukin-2 and 5-FU chemotherapy in patients with metastatic colorectal carcinoma

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971584

Overview of clinical trials using 5-fluorouracil and leucovorin for the treatment of colorectal cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971584

T cell growth factor: parameters of production and a quantitative microassay for activity

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971584

Preliminary analysis of a randomized comparison of 5-fluorouracil versus 5-fluorouracil and high-dose continuous-infusion folinic acid in disseminated colorectal cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971584

Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971584

Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 in disseminated melanoma [corrected].

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971584

5-Fluorouracil and folinic acid: interesting biochemistry or effective treatment?

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971584

Inhibition of lymphokine-activated killer cell generation by cultured tumor cell lines in vitro

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971584

Natural killer (NK)-like cytotoxic activity of allospecific T cell receptor-gamma,delta+ T cell clones. Distinct receptor-ligand interactions mediate NK-like and allospecific cytotoxicity.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971584

Reduced natural cytotoxic cell activity in patients receiving cisplatin-based chemotherapy and in mice treated with cisplatin

24 September 2018

1 reference

12 December 2020

Effects of chemotherapeutic agents on the immune response. I

1 reference

12 December 2020

Augmentation of the generation of cell-mediated cytotoxicity after a single dose of adriamycin in cancer patients

1 reference

12 December 2020

Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2

1 reference

12 December 2020

Effect of corticosteroid on the antitumor activity of lymphokine-activated killer cells and interleukin 2 in mice

1 reference

12 December 2020

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer

1 reference

12 December 2020

A T-cell receptor γ/CD3 complex found on cloned functional lymphocytes

1 reference

12 December 2020

Combined effects of chemotherapy and interleukin 2 in the therapy of mice with advanced pulmonary tumors

1 reference

12 December 2020

A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma

1 reference

12 December 2020

Chemotherapy subsequent to recombinant interleukin-2 immunotherapy: protocol for enhanced tumoricidal activity

1 reference

12 December 2020

Adoptive immunotherapy of human cancer using low-dose recombinant interleukin 2 and lymphokine-activated killer cells

1 reference

12 December 2020

Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.1990.436

1 reference

release_csxjadswefdsblv57yniwor5eq

11 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/csxjadswefdsblv57yniwor5eq

24 November 2022

mapped directly with Wikidata item

1 reference

11 August 2017

PubMed publication ID

2257211

1 reference